You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

Gallium-68 PET Imaging in Neuroendocrine Tumours

Version: n/a ID: PET 19 nov 2018
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
Authors:
S. Singh,, R. Poon,, R. Wong,, U. Metser, , PET Steering Committee

Guideline Objective

To provide a summary of evidence surrounding the clinical utility of Gallium-68 (68Ga) positron emission tomography (PET) imaging in patients with neuroendocrine tumours (NETs) and recommendations for their use in Ontario.

Patient Population

Adult and pediatric patients with suspected or diagnosed well-differentiated NETs

Intended Guideline Users

This recommendation report is intended to guide the Ontario PET Steering Committee with respect to the development of indications in the context of the patient management pathway. This recommendation report may also be useful to inform clinicians who are involved in the care of patients with NETs.

Research Questions

  • What benefit to clinical management does PET or PET/CT contribute to the initial diagnosis of NETs?
  • What benefit to clinical management does PET or PET/CT contribute to the staging and restaging of NETs?
  • What benefit to clinical management does PET or PET/CT contribute to the assessment of treatment response for NETs?
  • What benefit to clinical management does PET or PET/CT contribute to the routine surveillance of NETs?
pdf download Summary (PDF) (146.89 Ko)
pdf download Full Report (PDF) (585.68 Ko)